TherapeuticsMD (TXMD) Reports Q4 Loss of $0.10/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Noble Financial Lifts PT on TherapeuticsMD (TXMD) to $15; Sees Reduced TX 12-001HR Risk
March 11, 2015 11:47 AM EDTNoble Financial affirms TherapeuticsMD, Inc. (AMEX: TXMD) at Buy and nudges its price target from $14 up to $15 following Q4 results and update issued after markets closed Tuesday.
Analyst Nathan Cali noted that the bump higher in TXMD's price target stems from an increased cash balance, lowering the cost of capital by 5 points to 15 percent, and increasing risk-adjusted rNPV for TX 12-001HR, bioidentical estradiol/progesterone.
Cali also noted the following key points from the quarter and recent updates:
March 10th, 2015 reported relatively inline full year 2015 financial... More